We localize essential medicines and accelerate biotech discovery from our Special Economic Zone campus in Delta State, Nigeria. Our modular, export‑ready plant produces WHO‑compliant generics, rapid diagnostics, and supports IP licensing across Africa.
Over 70% of Africa’s medicines are imported. We are building resilient, on‑continent capacity to produce essential drugs, diagnostics, and biotech IP—reducing costs, stabilizing supply, and enabling equitable access across West, East, and Southern Africa.
Essential generics: ARVs, antimalarials, antibiotics, chronic care, oncology.
Rapid test kits (HIV, malaria, TB, HPV), PCR/ELISA reagents & clinical tools.
White‑label production and IP licensing with academic & industry partners.
ISO‑classified suites for oral solids, injectables, and aseptic processing with full QA/QC labs and stability testing.
Molecular biology, chromatography, PCR, and kit assembly lines supporting diagnostics and personalized medicine.
2–8°C and −20°C storage, export dispatch hub, and regional distribution nodes for last‑mile delivery.
We co‑develop solutions for oncology, infectious disease, and pediatric care. Our inventions are archived in a private, time‑stamped vault with tiered access for collaborators and partners.
Our labs combine molecular biology, bioinformatics, and advanced plant science to accelerate drug discovery.
Hybrid solar + CNG power, wastewater treatment, emissions control, and carbon‑credit monetization support greener, cost‑stable operations.
General Inquiries & Partnerships: contactus@grenebiopharma.org
We typically respond within 2–3 business days.